1208-75-9 Usage
General Description
1-BENZYL-HEXAHYDRO-4H-AZEPIN-4-ONE is a chemical compound that belongs to the class of benzylpiperidinones. It is a white solid that is used in the synthesis of various pharmaceuticals and research chemicals. 1-BENZYL-HEXAHYDRO-4H-AZEPIN-4-ONE is known for its potential as a psychoactive substance and has been the subject of research for its potential therapeutic properties. Its molecular structure contains a six-membered ring with a nitrogen atom, and its benzyl group provides unique properties that make it suitable for various applications in medicinal chemistry. Further research is being conducted to explore its potential pharmacological effects and applications in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 1208-75-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,2,0 and 8 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1208-75:
(6*1)+(5*2)+(4*0)+(3*8)+(2*7)+(1*5)=59
59 % 10 = 9
So 1208-75-9 is a valid CAS Registry Number.
InChI:InChI=1/C13H17NO/c15-13-7-4-9-14(10-8-13)11-12-5-2-1-3-6-12/h1-3,5-6H,4,7-11H2
1208-75-9Relevant articles and documents
-
Yokoo,Morosawa
, p. 631 (1956)
-
NOVEL COMPOUNDS
-
Paragraph 0489; 0490, (2013/06/26)
This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA
-
Page/Page column 98, (2013/06/27)
This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.